GE HealthCare Technologies Inc. (NASDAQ:GEHC) Stock Position Boosted by Chicago Partners Investment Group LLC

Chicago Partners Investment Group LLC boosted its stake in GE HealthCare Technologies Inc. (NASDAQ:GEHC) by 14.6% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 4,241 shares of the company’s stock after buying an additional 539 shares during the period. Chicago Partners Investment Group LLC’s holdings in GE HealthCare Technologies were worth $303,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Fortitude Family Office LLC bought a new position in GE HealthCare Technologies in the 4th quarter valued at about $29,000. Turtle Creek Wealth Advisors LLC bought a new position in shares of GE HealthCare Technologies during the 4th quarter valued at about $30,000. Sachetta LLC bought a new position in shares of GE HealthCare Technologies during the 4th quarter valued at about $31,000. Central Bank & Trust Co. bought a new position in shares of GE HealthCare Technologies during the 4th quarter valued at about $33,000. Finally, Valued Wealth Advisors LLC bought a new position in shares of GE HealthCare Technologies during the 4th quarter valued at about $33,000. Institutional investors own 82.06% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on GEHC shares. Argus raised their price objective on shares of GE HealthCare Technologies from $80.00 to $110.00 and gave the company a “buy” rating in a research report on Monday, April 1st. Evercore ISI raised their target price on shares of GE HealthCare Technologies from $93.00 to $100.00 and gave the stock an “outperform” rating in a report on Thursday, April 4th. Bank of America decreased their target price on shares of GE HealthCare Technologies from $94.00 to $86.00 and set a “neutral” rating for the company in a report on Wednesday, May 1st. Citigroup raised their target price on shares of GE HealthCare Technologies from $88.00 to $103.00 and gave the stock a “buy” rating in a report on Wednesday, April 3rd. Finally, The Goldman Sachs Group began coverage on shares of GE HealthCare Technologies in a report on Thursday, May 30th. They issued a “neutral” rating and a $87.00 target price for the company. Five research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $94.09.

GE HealthCare Technologies Price Performance

NASDAQ GEHC opened at $77.55 on Tuesday. The company has a 50 day simple moving average of $81.37 and a 200-day simple moving average of $81.23. The company has a debt-to-equity ratio of 1.11, a current ratio of 1.06 and a quick ratio of 0.83. The firm has a market capitalization of $35.40 billion, a price-to-earnings ratio of 22.68, a price-to-earnings-growth ratio of 2.75 and a beta of 1.22. GE HealthCare Technologies Inc. has a 52-week low of $62.35 and a 52-week high of $94.50.

GE HealthCare Technologies (NASDAQ:GEHC) last posted its quarterly earnings results on Tuesday, April 30th. The company reported $0.90 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.90. The business had revenue of $4.65 billion during the quarter, compared to analyst estimates of $4.80 billion. GE HealthCare Technologies had a net margin of 8.05% and a return on equity of 25.32%. The firm’s revenue was down 1.2% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.85 earnings per share. Equities research analysts predict that GE HealthCare Technologies Inc. will post 4.27 earnings per share for the current fiscal year.

GE HealthCare Technologies Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, May 15th. Investors of record on Friday, April 19th were given a dividend of $0.03 per share. This represents a $0.12 annualized dividend and a yield of 0.15%. The ex-dividend date of this dividend was Thursday, April 18th. GE HealthCare Technologies’s payout ratio is presently 3.51%.

Insider Activity at GE HealthCare Technologies

In related news, CEO Jan Makela sold 20,227 shares of the firm’s stock in a transaction that occurred on Monday, May 13th. The shares were sold at an average price of $81.57, for a total transaction of $1,649,916.39. Following the transaction, the chief executive officer now owns 63,348 shares of the company’s stock, valued at $5,167,296.36. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other GE HealthCare Technologies news, CEO Jan Makela sold 20,227 shares of the stock in a transaction that occurred on Monday, May 13th. The stock was sold at an average price of $81.57, for a total transaction of $1,649,916.39. Following the transaction, the chief executive officer now owns 63,348 shares in the company, valued at $5,167,296.36. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CTO Taha Kass-Hout sold 3,300 shares of the stock in a transaction that occurred on Tuesday, May 28th. The shares were sold at an average price of $78.70, for a total value of $259,710.00. Following the transaction, the chief technology officer now owns 67,300 shares in the company, valued at approximately $5,296,510. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 90,482 shares of company stock valued at $7,369,137. 0.27% of the stock is currently owned by corporate insiders.

About GE HealthCare Technologies

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics.